Custom synthesis | Naphthyridine | Pyrimidine | Indoline |
New Melocules

AP26113 1197958-12-5

AP26113 1197958-12-5

AP26113 (also known as Brigatinib) is an investigational small-molecule targeted cancer therapy being developed by ARIAD Pharmaceuticals, Inc. Brigatinib has exhibited activity as a potent dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR).

GMP is not available for AP26113, DMF for AP26113 is under preparation 
 
Disclaimer:Those products (AP26113 1197958-12-5) patented are for lab analytical & research purposes only.